<DOC>
	<DOCNO>NCT01815242</DOCNO>
	<brief_summary>The trial evaluate optimal treatment nab-paclitaxel combination either carboplatin gemcitabine patient triple negative breast cancer .</brief_summary>
	<brief_title>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment Therapy Response Prediction Early Breast Cancer - Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion Criteria Female patient , age diagnosis 18 year ( consider patient 70 year ADAPT Elderly ) Histologically confirm unilateral primary invasive carcinoma breast Clinical T1 T4 ( except inflammatory breast cancer ) All clinical N ( cN ) No clinical evidence distant metastasis ( M0 ) Known HR status HER2 status ( local pathology ) Tumor block available central pathology review Performance Status ECOG &lt; 1 KI &gt; 80 % Negative pregnancy test ( urine serum ) within 7 day prior start induction treatment premenopausal patient Written inform consent prior begin specific protocol procedure , include expect cooperation patient treatment followup , must obtain document accord local regulatory requirement The patient must accessible treatment followup Additional Inclusion Criteria patient receive chemotherapy : Laboratory requirement patient receive neoadjuvant chemotherapy ( within 14 day prior induction treatment ) : Leucocytes &gt; = 3.5 10^9/L Platelets &gt; = 100 10^9/L Hemoglobin &gt; = 10 g/dL Total bilirubin &lt; = 1 x ULN ASAT ( SGOT ) ALAT ( SGPT ) &lt; = 2.5 x UNL Creatinine &lt; = 175 µmol/L ( 2 mg/dl ) LVEF within normal limit institution measure echocardiography normal ECG ( within 42 day prior induction treatment ) Known hypersensitivity reaction compound incorporated substance Prior malignancy diseasefree survival &lt; 10 year , except curatively treat basalioma skin pTis cervix uteri Nonoperable breast cancer include inflammatory breast cancer Previous concurrent treatment cytotoxic agent reason consultation sponsor Concurrent treatment experimental drug . Participation another interventional clinical trial without investigational market drug within 30 day prior study entry Male breast cancer Concurrent pregnancy ; patient childbearing potential must implement highly effective ( less 1 % failure rate ) nonhormonal contraceptive measure study treatment Breast feeding woman Sequential breast cancer Reasons indicate risk poor compliance Patients able consent Additional Exclusion Criteria patient receive chemotherapy : Known polyneuropathy ≥ grade 2 Severe relevant comorbidity would interact application cytotoxic agent participation study include acute cystitis ischuria chronic kidney disease Uncompensated cardiac function Inadequate organ function include : Leucocytes &lt; 3.5 x 10^9/l Platelets &lt; 100 x 10^9/l Bilirubin normal limit Alkaline phosphatase &gt; 5 x UNL ASAT and/or ALAT associate AP &gt; 2.5 x UNL</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>